BR112014012460A2 - proteínas recombinantes e seus usos terapêuticos - Google Patents
proteínas recombinantes e seus usos terapêuticosInfo
- Publication number
- BR112014012460A2 BR112014012460A2 BR112014012460A BR112014012460A BR112014012460A2 BR 112014012460 A2 BR112014012460 A2 BR 112014012460A2 BR 112014012460 A BR112014012460 A BR 112014012460A BR 112014012460 A BR112014012460 A BR 112014012460A BR 112014012460 A2 BR112014012460 A2 BR 112014012460A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic uses
- recombinant proteins
- sequence
- epitopes
- receptors
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
resumo patente de invenção: "proteínas recombinantes e seus usos terapêuticos". a presente invenção refere-se a uma proteína recombinante que expressa um ou mais fatores de crescimento humanos, antígenos de tumor, e/ou seus receptores ou epítopos ou dentro de uma expressão imunogênica que cria uma proteína recombinante em que um ou mais epítopos são apresentados na superfície da sequência em sua configuração natural. a(s) sequência(s) de fatores de crescimento, antígenos de tumor e/ou receptores podem ser expressas dentro da sequência de codificação em posições internas apropriadas ou nos terminais como expressões simples ou como duas ou mais repetições em tandem.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563128P | 2011-11-23 | 2011-11-23 | |
US61/563,128 | 2011-11-23 | ||
US201261654401P | 2012-06-01 | 2012-06-01 | |
US61/654,401 | 2012-06-01 | ||
PCT/IB2012/002876 WO2013076580A2 (en) | 2011-11-23 | 2012-11-21 | Recombinant proteins and their therapeutic uses |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014012460A2 true BR112014012460A2 (pt) | 2017-06-06 |
BR112014012460B1 BR112014012460B1 (pt) | 2021-01-12 |
Family
ID=47716105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014012460-4A BR112014012460B1 (pt) | 2011-11-23 | 2012-11-21 | proteínas recombinantes |
Country Status (22)
Country | Link |
---|---|
US (4) | US9902760B2 (pt) |
EP (2) | EP3744343A1 (pt) |
JP (4) | JP6121436B2 (pt) |
KR (2) | KR102274211B1 (pt) |
CN (3) | CN104066447A (pt) |
AU (3) | AU2012342117B2 (pt) |
BR (1) | BR112014012460B1 (pt) |
CA (1) | CA2856255C (pt) |
DK (1) | DK2782598T3 (pt) |
ES (1) | ES2812564T3 (pt) |
HR (1) | HRP20201282T1 (pt) |
HU (1) | HUE050438T2 (pt) |
IL (2) | IL232645B (pt) |
LT (1) | LT2782598T (pt) |
MX (1) | MX354902B (pt) |
MY (2) | MY184576A (pt) |
PL (1) | PL2782598T3 (pt) |
PT (1) | PT2782598T (pt) |
RS (1) | RS60782B1 (pt) |
RU (2) | RU2650574C2 (pt) |
SI (1) | SI2782598T1 (pt) |
WO (1) | WO2013076580A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014012460B1 (pt) * | 2011-11-23 | 2021-01-12 | Bioven 3 Limited | proteínas recombinantes |
US20160333087A1 (en) * | 2015-05-12 | 2016-11-17 | Bioven 3 Limited | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
CA3070034A1 (en) * | 2017-07-18 | 2019-01-24 | In3Bio Ltd. | Synthetic proteins and therapeutic uses thereof |
CN107880133A (zh) * | 2017-11-04 | 2018-04-06 | 海南大学 | 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法 |
WO2019179361A1 (zh) * | 2018-03-21 | 2019-09-26 | 傅惠芳 | 改善括约肌闭锁不全的组合物及其医药组成物与用途 |
WO2020046982A1 (en) * | 2018-08-27 | 2020-03-05 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating virus infection |
BR112021026132A2 (pt) * | 2019-06-25 | 2022-02-08 | In3Bio Ltd | Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas |
US20220378891A1 (en) | 2019-11-07 | 2022-12-01 | In3Bio Ltd. | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors |
CN116003601A (zh) * | 2019-12-05 | 2023-04-25 | 启愈生物技术(上海)有限公司 | 一种抗pd-l1纳米抗体及其用途 |
WO2021195327A1 (en) * | 2020-03-25 | 2021-09-30 | The Regents Of The University Of Colorado, A Body Corporate | Bivalent egf fusion toxins |
CN113735980A (zh) * | 2021-08-23 | 2021-12-03 | 中国医学科学院北京协和医院 | 一种自融合串联蛋白修饰方法及其应用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
CA2137639C (en) * | 1993-12-09 | 1999-01-26 | Agustin B. L. Davila | Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases |
CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
CA2302522C (en) | 1997-08-29 | 2010-08-17 | Aquila Biopharmaceuticals, Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
EP1030684A4 (en) * | 1997-11-14 | 2004-09-15 | Euro Celtique Sa | MODIFIED ANTIBODIES WITH IMPROVED CAPACITY TO TRIGGER ANTI-IDIOTYPE RESPONSE |
US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
EP2322210A1 (en) | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
US7078486B2 (en) * | 1999-12-10 | 2006-07-18 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
US7201905B2 (en) * | 2000-03-23 | 2007-04-10 | Greenville Hospital System | Bi-functional cancer treatment agents |
CU22999A1 (es) | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | Método de tratamiento de enfermedades malignas e infecciosas crónicas |
EP1390065A2 (en) * | 2001-05-14 | 2004-02-25 | Duotol Ab | Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
CN1966525A (zh) * | 2001-06-13 | 2007-05-23 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
JP2004538331A (ja) | 2001-08-17 | 2004-12-24 | ロジャー ウィリアムス ホスピタル | インサイチュ免疫法 |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
JP2005528107A (ja) * | 2002-05-31 | 2005-09-22 | シェジェン ピーティーワイ リミテッド | 膜転位置配列由来の自己合体または自己凝集キメラタンパク質 |
AU2003900481A0 (en) * | 2003-02-05 | 2003-02-20 | Queensland University Of Technology | Synthetic modulators of cell migration and growth |
US8207314B2 (en) * | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
US7601341B2 (en) * | 2003-06-05 | 2009-10-13 | Research Development Foundation | Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
JP4623625B2 (ja) * | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型5量体組換えワクチン |
US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
EP2634252B1 (en) * | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
CN1686562A (zh) * | 2005-03-31 | 2005-10-26 | 南京大学 | 一种转铁蛋白与生物还原剂的结合物及其制备方法 |
BRPI0707679A2 (pt) * | 2006-02-01 | 2011-05-10 | Tjhe Johns Hopkins University | conjugado de polipetÍdeo - Àcido nuclÉico para imunoprofilaxia ou imunoterapia para distérbios neoplÁsticos ou infecciosos |
ATE473758T1 (de) | 2006-04-13 | 2010-07-15 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Her-2/neu multipeptidimpfstoff |
SI2041177T1 (sl) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
JP2009543071A (ja) * | 2006-07-06 | 2009-12-03 | モレキュラー ロジックス,インコーポレイテッド | ドミナントネガティブリガンド薬物発見システム |
WO2008030988A2 (en) * | 2006-09-06 | 2008-03-13 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
CN1995064A (zh) * | 2006-12-20 | 2007-07-11 | 李欣越 | 增强生物活性的长效重组人红细胞生长因子融合蛋白及方法 |
CN101679508B (zh) * | 2007-02-02 | 2014-11-05 | 贝勒研究院 | 基于靶向抗原至抗原呈递细胞上表达的dcir的疫苗 |
NZ592859A (en) * | 2007-02-02 | 2012-05-25 | Baylor Res Inst | Multivariable antigens complexed with targeting humanized monoclonal antibody |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
JP2011187653A (ja) | 2010-03-08 | 2011-09-22 | Olympus Corp | 防水機器 |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
BR112014012460B1 (pt) * | 2011-11-23 | 2021-01-12 | Bioven 3 Limited | proteínas recombinantes |
-
2012
- 2012-11-21 BR BR112014012460-4A patent/BR112014012460B1/pt active IP Right Grant
- 2012-11-21 CA CA2856255A patent/CA2856255C/en active Active
- 2012-11-21 LT LTEP12824705.3T patent/LT2782598T/lt unknown
- 2012-11-21 MY MYPI2014701320A patent/MY184576A/en unknown
- 2012-11-21 KR KR1020197027075A patent/KR102274211B1/ko active IP Right Grant
- 2012-11-21 JP JP2014542952A patent/JP6121436B2/ja active Active
- 2012-11-21 RU RU2014124923A patent/RU2650574C2/ru active
- 2012-11-21 WO PCT/IB2012/002876 patent/WO2013076580A2/en active Application Filing
- 2012-11-21 HU HUE12824705A patent/HUE050438T2/hu unknown
- 2012-11-21 RS RS20200986A patent/RS60782B1/sr unknown
- 2012-11-21 MY MYPI2018000286A patent/MY188083A/en unknown
- 2012-11-21 EP EP20170470.7A patent/EP3744343A1/en not_active Withdrawn
- 2012-11-21 PL PL12824705T patent/PL2782598T3/pl unknown
- 2012-11-21 CN CN201280067891.1A patent/CN104066447A/zh active Pending
- 2012-11-21 EP EP12824705.3A patent/EP2782598B1/en active Active
- 2012-11-21 US US13/813,844 patent/US9902760B2/en active Active
- 2012-11-21 ES ES12824705T patent/ES2812564T3/es active Active
- 2012-11-21 KR KR1020147016995A patent/KR102024066B1/ko active IP Right Grant
- 2012-11-21 CN CN201810569766.XA patent/CN108864291A/zh active Pending
- 2012-11-21 AU AU2012342117A patent/AU2012342117B2/en active Active
- 2012-11-21 PT PT128247053T patent/PT2782598T/pt unknown
- 2012-11-21 SI SI201231830T patent/SI2782598T1/sl unknown
- 2012-11-21 DK DK12824705.3T patent/DK2782598T3/da active
- 2012-11-21 MX MX2014006232A patent/MX354902B/es active IP Right Grant
- 2012-11-21 CN CN201810569310.3A patent/CN108864261A/zh active Pending
-
2014
- 2014-05-15 IL IL232645A patent/IL232645B/en active IP Right Grant
-
2016
- 2016-01-15 US US14/996,553 patent/US20160207972A1/en not_active Abandoned
-
2017
- 2017-03-29 JP JP2017064763A patent/JP6570081B2/ja not_active Expired - Fee Related
- 2017-11-16 US US15/814,723 patent/US11198716B2/en active Active
- 2017-11-30 AU AU2017268634A patent/AU2017268634B2/en not_active Ceased
-
2018
- 2018-03-09 RU RU2018108421A patent/RU2766595C2/ru active
-
2019
- 2019-04-04 JP JP2019072235A patent/JP6953467B2/ja active Active
-
2020
- 2020-02-21 AU AU2020201297A patent/AU2020201297B2/en not_active Ceased
- 2020-08-14 HR HRP20201282TT patent/HRP20201282T1/hr unknown
- 2020-12-22 IL IL279676A patent/IL279676A/en unknown
-
2021
- 2021-09-29 JP JP2021159307A patent/JP7470669B2/ja active Active
- 2021-11-08 US US17/521,121 patent/US20220153798A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014012460A2 (pt) | proteínas recombinantes e seus usos terapêuticos | |
CY1123404T1 (el) | Αντι-girt αντισωματα | |
CO7151522A2 (es) | Proteínas de fusión de interleuquina-10 y usos de las mismas | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
CU24206B1 (es) | Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos | |
BR112014018630A2 (pt) | alvejamento de glicanos de sulfato de condroitina | |
BR112016020368A2 (pt) | proteínas fc multiméricas | |
MY175708A (en) | Dna antibody constructs and method of using same | |
CR20120404A (es) | Proteinas de enlace cd127 | |
WO2015089492A3 (en) | Dna antibody constructs and method of using same | |
AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
NZ711567A (en) | Antibody formulations | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
PH12015501870B1 (en) | Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof | |
EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
PE20081687A1 (es) | Proteina de fusion | |
PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
BR112015023651A2 (pt) | expressão aumentada de proteínas de picornavírus | |
BR112014001287A2 (pt) | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |